Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the prevalence and treatment of benign prostatic hyperplasia and reports no new findings; it emphasizes considering side effects and comorbidities in therapy choices.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

This study found that PRO 160/120 and Finasteride showed similar effectiveness in improving urinary symptoms and quality of life in patients with benign prostatic hyperplasia over 48 weeks.

This study found that methylation of the 5-AR 2 promoter region may lead to low or absent 5-AR 2 protein expression in some human adult prostate tissues.

This review discusses current treatments for benign prostatic hyperplasia and reports on the cost-effectiveness of alpha1-selective adrenergic receptor antagonists compared to other pharmacologic and invasive therapies without presenting new clinical results.

This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.

This study reports a novel homozygous mutation in the DST gene causing a unique form of epidermolysis bullosa simplex with prurigo papules in a 39-year-old Syrian man.

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

This research suggests that the enzyme Phospholipase D from E. coli is a strong candidate as the underlying cause of benign prostatic hyperplasia, potentially mediated by its conversion to lysophosphatidic acid in the prostate.

Combination therapy for BPH is cost-effective, especially for men with larger prostates.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

This review reports that combination therapy with 5α-reductase inhibitors and α1-receptor blockers does not appear to benefit patients with benign prostatic hyperplasia and prostate volumes up to 40–45 ml, but may be more effective for larger prostate volumes.

This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.

This study explored the effects of a 50% hydroalcoholic UPBF extract on BPH in testosterone propionate-induced rats, finding significant improvements in prostate-related parameters and lower urinary tract symptoms at a 200 mg/kg dose, suggesting potential use in BPH management.

Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.

This study found that topical BPM31543 was safe, tolerable, and showed potential to reduce chemotherapy-induced alopecia at higher dosing levels among adult women with cancer receiving taxane-based chemotherapy.

In this study, researchers found that using a 5-α reductase inhibitor may reduce inflammation-related cytokines associated with T-helper cell 1 and T-helper cell 2 in prostate tissues after surgery, but it did not affect those related to Th17 cells.

This study found that Croton membranaceus root extract induced CYP1A2 and GSTM1 enzymes but inhibited CYP3A4 and CYP2D6 in rat livers, suggesting caution in its use with other drugs.

This study found that men with depression, erectile dysfunction, and marijuana usage were more likely to be treated for lower urinary tract symptoms, while alcohol use was not significantly associated.

In this study, the ethanol extract of Zapoteca portoricensis stem significantly reduced markers of testosterone-induced benign prostate hyperplasia in male albino rats without harming liver and kidney function.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

This research explores the pathogenesis of benign prostatic hyperplasia and evaluates the combined effect of finasteride and anastrozole in treating BPH in a rat model, but reports no new results yet.

This study is designed to explore the pathogenesis of BPH and assess the effectiveness of combining finasteride and anastrozole as a treatment in rats, with a focus on genetic polymorphisms and hormone regulation.

This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This study reported that Cosmos caudatus extract alone may therapeutically modulate the AR–FGF-2 axis in a BPH rat model, comparable to finasteride, but combining them disrupted pathway regulation, increasing TGF-β levels.